Thornburg Investment Management Inc. Sells 1,421 Shares of Insulet Corporation $PODD

Thornburg Investment Management Inc. lowered its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 8.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 15,049 shares of the medical instruments supplier’s stock after selling 1,421 shares during the quarter. Thornburg Investment Management Inc.’s holdings in Insulet were worth $4,728,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Cetera Investment Advisers boosted its stake in shares of Insulet by 167.0% during the first quarter. Cetera Investment Advisers now owns 6,455 shares of the medical instruments supplier’s stock valued at $1,695,000 after purchasing an additional 4,037 shares during the period. HB Wealth Management LLC lifted its holdings in Insulet by 48.9% during the 1st quarter. HB Wealth Management LLC now owns 2,280 shares of the medical instruments supplier’s stock valued at $599,000 after buying an additional 749 shares in the last quarter. Mackenzie Financial Corp boosted its position in Insulet by 39.9% in the 1st quarter. Mackenzie Financial Corp now owns 10,576 shares of the medical instruments supplier’s stock valued at $2,777,000 after buying an additional 3,015 shares during the period. Ramirez Asset Management Inc. bought a new position in Insulet in the 1st quarter worth about $53,000. Finally, Banque Cantonale Vaudoise purchased a new position in shares of Insulet during the first quarter worth approximately $1,575,000.

Insulet Stock Down 0.6%

NASDAQ:PODD opened at $326.80 on Thursday. The company’s 50-day simple moving average is $322.19 and its 200-day simple moving average is $316.21. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.81 and a current ratio of 2.26. Insulet Corporation has a fifty-two week low of $230.05 and a fifty-two week high of $354.88. The stock has a market capitalization of $22.99 billion, a P/E ratio of 99.33, a P/E/G ratio of 2.64 and a beta of 1.39.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. The company had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. Insulet had a net margin of 10.01% and a return on equity of 23.78%. Insulet’s revenue for the quarter was up 29.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.08 earnings per share. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on PODD. Raymond James Financial increased their price objective on Insulet from $366.00 to $385.00 and gave the stock an “outperform” rating in a research note on Friday, November 21st. Jefferies Financial Group lifted their price objective on Insulet from $375.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Morgan Stanley reiterated an “overweight” rating on shares of Insulet in a report on Thursday, August 7th. Stifel Nicolaus initiated coverage on shares of Insulet in a research report on Tuesday, October 21st. They set a “buy” rating and a $370.00 target price on the stock. Finally, Rothschild & Co Redburn upped their price target on shares of Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a research report on Friday, October 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $379.65.

Insider Activity

In other news, SVP Laetitia Cousin sold 797 shares of the company’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP Prem Singh sold 687 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.39% of the company’s stock.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.